Trump's trade deals with the EU and Japan pave the way for the stock market to end with it's third straight annual gain of ...

Oppenheimer Asset Management on Monday raised its year-end target for the S&P 500 index to 7,100, the highest among major ...

Just a few years before 2023’s Barbenheimer phenomenon, Margot Robbie starred in a complex biopic that was much Oppenheimer ...

Sarepta Therapeutics ( NASDAQ: SRPT) was upgraded to Neutral from Underweight at J.P. Morgan as it sees FDA's Elevidys hold removal recommendation in ambulatory patients as a clear win.

Carvana Co. (NYSE:CVNA) is one of the best multibagger stocks according to hedge funds. On July 25, 2025, Oppenheimer analyst ...

Analysts upgraded Carvana shares, arguing the company is a "digitally-driven disruptor" in the fractured used car market.

There are many hugely impressive things about the film – not least the central, Oscar-winning, performance from Cillian ...

The strategist — an industry veteran of 40 years who joined Goldman Sachs in 2002 — spoke to Bloomberg News about the outlook ...

Shares of Sarepta Therapeutics surged Tuesday morning after the company said it had been informed by the Food and Drug Administration that it could resume shipping a drug it paused sales of last week.

Visa and Mastercard are expected to report higher quarterly profits this week on steady consumer spending, and analysts will ...

This isn’t a generic re-run. These screenings are a testament to Nolan’s continued support for the IMAX format and enable ...

Oppenheimer analyst Brian Nagel sees upside in Carvana stock to $450. CVNA is set to report its fiscal second-quarter ...